AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29336182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactococcus lactis subsp. cremoris FC
Number of subjects: 31
Study 29336182 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented gelled milk (placebo)
Number of subjects: 31
Study 27462096 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered nurse-organized service programs
Number of subjects: 200
Study 27462096 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 200
Study 24665163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300mg orally once daily for 3 months
Number of subjects: 80
Study 24665163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ALA supplementation)
Number of subjects: 80
Study 24665163 — intervention group
Group type: COMPARATOR
Intervention: Control group (ALA supplementation)
Number of subjects: 80
Study 22569899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor + Clopidogrel
Number of subjects: 234
Study 22569899 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Clopidogrel
Number of subjects: 234
Study 22569899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 234
Study 20569031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera cream
Number of subjects: 49
Study 20569031 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 49
Study 17907231 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 63
Study 17907231 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 63
Study 16159849 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 14293
Study 16159849 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 14293
Study 12605586 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.56 g x day(‐1) x kg(‐1))
Number of subjects: 17
Study 12605586 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study 10952476 — intervention group
Group type: COMPARATOR
Intervention: MS Contin tablets (MSC)
Number of subjects: 25
Study 10952476 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate suppository (MSR)
Number of subjects: 25
Study 10952476 — intervention group
Group type: EXPERIMENTAL
Intervention: MSR
Number of subjects: 25
Study 10952476 — intervention group
Group type: COMPARATOR
Intervention: MSC
Number of subjects: 25
Study 8975964 — intervention group
Group type: EXPERIMENTAL
Intervention: α-interferon treatment
Number of subjects: 2927
Study 1547765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD) 20 mg b.i.d. for 4 weeks
Number of subjects: 22
Study 1547765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD) 40 mg b.i.d. for 4 weeks
Number of subjects: 22
Study 1547765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD)
Number of subjects: 22
Study 1547765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2416190 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 11
Study 2416190 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study 3113957 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol plus intravenous nitroglycerin (Group 2)
Number of subjects: 14
Study 3113957 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol alone (Group 1)
Number of subjects: 14
Study 31797407 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism
Number of subjects: 64
Study 31797407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot assistant
Number of subjects: 42
Study 30894423 — intervention group
Group type: COMPARATOR
Intervention: Nurse
Number of subjects: 42
Study 28933582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rohto® Hydra (0.01% menthol)
Number of subjects: 48
Study 28933582 — intervention group
Group type: COMPARATOR
Intervention: Systane® Ultra treatments
Number of subjects: 48
Study 24993741 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple eradication treatment for H. pylori
Number of subjects: 370
Study 23525529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration group (n = 100)
Number of subjects: 150
Study 23525529 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 150
Study 21561619 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 gauge Quincke needle
Number of subjects: 53
Study 21561619 — intervention group
Group type: COMPARATOR
Intervention: 25 gauge Quincke needle
Number of subjects: 53
Study 21561619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 19447597 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine and neostigmine (500 microg neostigmine and 75 microg clonidine)
Number of subjects: 70
Study 19447597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain saline)
Number of subjects: 70
Study 16847013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (chloramphenicol eye drops; n = 104)
Number of subjects: 307
Study 16847013 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotics (n = 109)
Number of subjects: 307
Study 16847013 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (controls; n = 94)
Number of subjects: 307
Study 16847013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (n = 104)
Number of subjects: 307
Study 15193674 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg twice daily for six months
Number of subjects: 700
Study 15193674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 15193674 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 700
Study 10960931 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and its modulation (specific agent, dose, and route not detailed)
Number of subjects: 279
Study 10960931 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment at randomization and weeks 6, 11, and 21 post-randomization
Number of subjects: 279
Study 9316554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hepatitis B vaccine (40 micrograms at 0, 1, 2, and 6 months)
Number of subjects: 110
Study 9316554 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose hepatitis B vaccine (20 micrograms at 0.1, and 6 months)
Number of subjects: 110
Study 8403467 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical n‐6 essential fatty acids (evening primrose oil) added to 0.1% betamethasone valerate
Number of subjects: 24
Study 8403467 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate twice daily for 3 weeks
Number of subjects: 24
Study 8403467 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 3744133 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH) 240 anti‐Xa U/kg/12 h
Number of subjects: 54
Study 3744133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin Fragmin 240 anti‐Xa U/kg/12 h
Number of subjects: 54
Study 3744133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin Fragmin 120 anti‐Xa U/kg/12 h
Number of subjects: 54
Study 3744133 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Fragmin 120 anti‐Xa U/kg 2 times daily
Number of subjects: 54
Study 29846739 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Inventory (PSI)
Number of subjects: 78
Study 26947719 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (up to 300 units), administered subcutaneously, two injections 12 weeks apart.
Number of subjects: 152
Study 26947719 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously, two injections 12 weeks apart.
Number of subjects: 152
Study 24401022 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chlorambucil
Number of subjects: 781
Study 24401022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus chlorambucil
Number of subjects: 781
Study 24401022 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 781
Study 24401022 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chlorambucil vs. Rituximab plus chlorambucil
Number of subjects: 781
Study 22874517 — intervention group
Group type: EXPERIMENTAL
Intervention: LPVr/ZDV/3TC
Number of subjects: 50
Study 22874517 — intervention group
Group type: COMPARATOR
Intervention: LPVr/NVP
Number of subjects: 50
Study 20555135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 21
Study 20555135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 18507107 — intervention group
Group type: EXPERIMENTAL
Intervention: suspension-emulsion
Number of subjects: 60
Study 18507107 — intervention group
Group type: EXPERIMENTAL
Intervention: emulsion with a 7:3 mixture of lipiodol and contrast medium
Number of subjects: 60
Study 18507107 — intervention group
Group type: EXPERIMENTAL
Intervention: suspension
Number of subjects: 60
Study 16430010 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 33
Study 16430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop
Number of subjects: 33
Study 16430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 33
Study 16430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE + One Step Plus
Number of subjects: 33
Study 16430010 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: AdheSE
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: Optibond Solo Plus
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: Adper Scotchbond 1
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: Optibond Solo Plus self‐etching
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 33
Study 16430010 — intervention group
Group type: COMPARATOR
Intervention: Adper Scotchbond MP
Number of subjects: 33
Study 12816878 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 egg yolks daily
Number of subjects: 197
Study 12816878 — intervention group
Group type: COMPARATOR
Intervention: 2 egg yolks daily
Number of subjects: 197
Study 10360660 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg m(‐2) by 24‐h intravenous infusion + cisplatin
Number of subjects: 0
Study 10360660 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg m(‐2) by 24‐h intravenous infusion + cisplatin + granulocyte colony‐stimulating factor (G‐CSF)
Number of subjects: 0
Study 10360660 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg m(‐2) + cisplatin administered as an outpatient by 3‐h infusion
Number of subjects: 0
Study 10360660 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/cisplatin
Number of subjects: 0
Study 10360660 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin compared with historical controls treated with best supportive care
Number of subjects: 0
Study 7741793 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleno-peptides (SPS 1187, Solcosplen)
Number of subjects: 256
Study 7741793 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen (E2) substitution (4 mg)
Number of subjects: 256
Study 2126836 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg 3 times daily for 2 weeks)
Number of subjects: 20
Study 2126836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7296520 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigation to rule out non-bronchial primary adenocarcinomas
Number of subjects: 87
Study 7296520 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bronchial tumor investigation
Number of subjects: 87
Study 7296520 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive investigation methods
Number of subjects: 87
Study 7296520 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of investigations
Number of subjects: 87
Study 31739120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine at 25 °C
Number of subjects: 220
Study 31739120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine at 37 °C (warm PI)
Number of subjects: 220
Study 31739120 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate with alcohol at 25 °C
Number of subjects: 220
Study 31739120 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate with alcohol at 37 °C (warm CH)
Number of subjects: 220
Study 29420589 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching bipolar radiofrequency ablation (SB-RFA) using internally cooled-wet electrodes
Number of subjects: 69
Study 29420589 — intervention group
Group type: COMPARATOR
Intervention: Switching monopolar radiofrequency ablation (SM-RFA) using separable clustered electrodes
Number of subjects: 69
Study 27064975 — intervention group
Group type: COMPARATOR
Intervention: IM20 × 3 (3 intramuscular standard-dose injections of 20-μg at weeks 0, 4, and 24)
Number of subjects: 437
Study 27064975 — intervention group
Group type: EXPERIMENTAL
Intervention: IM40 × 4 (4 intramuscular double-dose injections of 40-μg at weeks 0, 4, 8, and 24)
Number of subjects: 437
Study 27064975 — intervention group
Group type: COMPARATOR
Intervention: ID4 × 4 (4 intradermal low-dose injections of 4-μg at weeks 0, 4, 8, and 24)
Number of subjects: 437
Study 24806825 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor mobility rehabilitation programme delivered by 29 NHS therapists for up to 12 sessions over 4 months.
Number of subjects: 568
Study 24806825 — intervention group
Group type: COMPARATOR
Intervention: Control group received verbal advice and transport and outdoor mobility leaflets prior to randomisation.
Number of subjects: 568
Study 22301477 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg
Number of subjects: 90
Study 22301477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20584070 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan at 80 mg day(‐1)
Number of subjects: 30
Study 20584070 — intervention group
Group type: COMPARATOR
Intervention: enalapril at 10 mg day(‐1)
Number of subjects: 30
Study 20584070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both telmisartan and enalapril
Number of subjects: 30
Study 17675590 — intervention group
Group type: EXPERIMENTAL
Intervention: BKB-SIN
Number of subjects: 96
Study 17675590 — intervention group
Group type: EXPERIMENTAL
Intervention: HINT
Number of subjects: 96
Study 17675590 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickSIN
Number of subjects: 96
Study 17675590 — intervention group
Group type: EXPERIMENTAL
Intervention: WIN
Number of subjects: 96
Study 15715914 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Activation Programme (EAP) in addition to usual care
Number of subjects: 0
Study 15715914 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 12401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with Step II dietary goals (≤30% of total calories from fat, <7% of calories from saturated fat, daily dietary cholesterol <200 mg)
Number of subjects: 13777
Study 12401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a college degree
Number of subjects: 13777
Study 12401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiovascular event
Number of subjects: 13777
Study 12401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of five or more daily servings of fruits or vegetables
Number of subjects: 13777
Study 12401533 — intervention group
Group type: COMPARATOR
Intervention: Being married, smoking, a sedentary lifestyle, and a higher body mass index
Number of subjects: 13777
Study 12401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary compliance
Number of subjects: 13777
Study 10099039 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/d isradipine
Number of subjects: 48
Study 10099039 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/d isradipine
Number of subjects: 48
Study 10099039 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg/d isradipine
Number of subjects: 48
Study 10099039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7858046 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 49
Study 7858046 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 49
Study 2574049 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg twice a day)
Number of subjects: 21
Study 2574049 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 29469638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 29469638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27423381 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA expression profiling (miScript miRNA PCR Array)
Number of subjects: 41
Study 24977688 — intervention group
Group type: COMPARATOR
Intervention: Modified ultrafiltration for 10 minutes (Group 1)
Number of subjects: 60
Study 24977688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration for 15 minutes (Group 2)
Number of subjects: 60
Study 24977688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration for 20 minutes (Group 3)
Number of subjects: 60
Study 22315014 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss therapy
Number of subjects: 40
Study 20049572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular infusion with 300 mL ropivacaine 0.2% at a speed of 5 mL/hour
Number of subjects: 50
Study 20049572 — intervention group
Group type: COMPARATOR
Intervention: Saline solution at an infusion speed of 5 mL/hour (Control)
Number of subjects: 50
Study 17761020 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG)
Number of subjects: 31
Study 17761020 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 31
Study 15795204 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with cannulated screws
Number of subjects: 60
Study 15795204 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty using an uncemented Austin Moore prosthesis
Number of subjects: 60
Study 12508961 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2-4 mg/day)
Number of subjects: 15
Study 12508961 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 15
Study 9439220 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-on formula
Number of subjects: 100
Study 9439220 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 100
Study 1659975 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin (600 mg)
Number of subjects: 131
Study 1659975 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 131
Study 6790805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of nitroglycerin
Number of subjects: 60
Study 6790805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 60
Study 30578550 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) using dense polytetrafluoroethylene (dPTFE) barrier membrane and mineralized cortical particulate freeze-dried bone allograft (FDBA)
Number of subjects: 84
Study 30578550 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR with membrane fixation
Number of subjects: 84
Study 30578550 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated initial ridge width
Number of subjects: 84
Study 30578550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall GBR procedure
Number of subjects: 84
Study 28742505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hops dry extract (Melcalin hops); 0.2 gr capsules once daily for 4 weeks
Number of subjects: 36
Study 28742505 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 0.2 gr capsules once daily for 4 weeks
Number of subjects: 36
Study 25488309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-first group (received fentanyl then midazolam)
Number of subjects: 65
Study 25488309 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-first group (received midazolam then fentanyl)
Number of subjects: 65
Study 25488309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 24612233 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 90
Study 24612233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22106952 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative home care
Number of subjects: 186
Study 22106952 — intervention group
Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 186
Study 19317822 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 1041
Study 19317822 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 1041
Study 19317822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 19317822 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 1041
Study 16680561 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (50 mg) alone
Number of subjects: 17
Study 16680561 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg) with cinacalcet (90 mg for 7 days)
Number of subjects: 17
Study 15216539 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Peel
Number of subjects: 60
Study 15216539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11436672 — intervention group
Group type: EXPERIMENTAL
Intervention: Active movement
Number of subjects: 39
Study 11436672 — intervention group
Group type: COMPARATOR
Intervention: Passive movement
Number of subjects: 39